Business Development Partnerships

Translating Science into Solutions through Strategic Partnerships

At Celgene, we know that finding the most innovative, effective and safe treatment options for patients extends beyond our walls. We constantly evaluate collaboration opportunities that complement our internal research efforts and strategically align with our mission and vision.

We actively seek discovery and development partners in areas such as: developing novel targeted therapies, next generation biologics, protein homeostasis, epigenetics, immunotherapy, stem cell therapy, combination treatments and more.

Below is a list of external collaborators that we work with in our R&D efforts:

  • Abide
  • Acceleron
  • Adimab
  • Agios
  • AnaptysBio
  • Anokion
  • Array BioPharma
  • AstraZeneca / MedImmune
  • bluebird bio
  • Blueline Biosciences
  • BMS
  • Concert
  • Epizyme
  • Evotec
  • Forma Therapeutics
  • GEMoaB
  • GlobeImmune
  • Herbert Irving Comprehensive Cancer Center
    at Columbia University Medical Center
  • Highline Therapeutics
  • Inception IBD
  • Jounce Therapeutics
  • Juno Therapeutics
  • Ligand
  • Lycera
  • Moffitt Cancer Center
  • NantBioscience
  • Nogra
  • Northern Biologics
  • Nurix
  • OncoMed Pharmaceuticals
  • PharmAkea Therapeutics
  • Recombinant Antibody Network (RAN)
  • Sanford Burnham Medical Research Institute
  • Sidney Kimmel Comprehensive Cancer Center
    at Johns Hopkins
  • Sutro BioPharma
  • Tisch Cancer Institute at the Icahn School of Medicine
    at Mount Sinai
  • Triphase
  • University of Pennsylvania
  • VentiRx Pharmaceuticals
  • Zymeworks
If you are interested in partnering with us, please Contact Us to reach our Business Development team.